CONTEXT: 21-hydroxylase deficiency (21OHD) is a common genetic disorder caused by mutations in the CYP21A2 gene, which encodes the adrenal 21-hydroxylase, microsomal P450c21. CYP21A2 gene mutations generally correlate well with impaired P450c21 enzymatic activity and the clinical findings in 21OHD, but occasional discrepancies between genotype and phenotype suggest the effects of modifier genes. Mutations in P450 oxidoreductase (POR), the protein that transfers electrons from reduced nicotinamide adenine dinucleotide phosphate to all microsomal P450s, can ameliorate the 21OHD phenotype and, therefore, could be a modifier gene. OBJECTIVES: We sought to identify POR variants in patients with 21OHD having discordant phenotype and genotype, and to evaluate their effect on 21-hydroxylase activity. PATIENTS AND METHODS: We determined the CYP21A2 genotypes of 313 Brazilian patients with 21OHD and correlated the genotype and phenotype. The POR gene was sequenced in 17 patients with discordant genotype and phenotype. Wild-type and A503V POR, and P450c21 were expressed in bacteria and reconstituted in vitro. Activities were assayed by conversion of [(14)C]progesterone to deoxycorticosterone and [(3)H]17-hydroxyprogesterone to 11-deoxycortisol, and assessed by thin layer chromatography and phosphorimaging. RESULTS: The A503V POR variant was found in 10 of 30 alleles, the same ratio as in the normal population. There were no significant differences in Michaelis constant, maximum velocity and maximum velocity/Michaelis constant of 21-hydroxylase activity supported by wild-type and A503V POR. CONCLUSION: The only POR missense polymorphism found in atypical 21OHD patients was A503V. Although A503V reduces P450c17 enzymatic activity, it does not influence P450c21 activity, indicating that POR A503V does not modify the 21OHD phenotype.
CONTEXT: 21-hydroxylase deficiency (21OHD) is a common genetic disorder caused by mutations in the CYP21A2 gene, which encodes the adrenal 21-hydroxylase, microsomal P450c21. CYP21A2 gene mutations generally correlate well with impaired P450c21 enzymatic activity and the clinical findings in 21OHD, but occasional discrepancies between genotype and phenotype suggest the effects of modifier genes. Mutations in P450 oxidoreductase (POR), the protein that transfers electrons from reduced nicotinamide adenine dinucleotide phosphate to all microsomal P450s, can ameliorate the 21OHD phenotype and, therefore, could be a modifier gene. OBJECTIVES: We sought to identify POR variants in patients with 21OHD having discordant phenotype and genotype, and to evaluate their effect on 21-hydroxylase activity. PATIENTS AND METHODS: We determined the CYP21A2 genotypes of 313 Brazilian patients with 21OHD and correlated the genotype and phenotype. The POR gene was sequenced in 17 patients with discordant genotype and phenotype. Wild-type and A503V POR, and P450c21 were expressed in bacteria and reconstituted in vitro. Activities were assayed by conversion of [(14)C]progesterone to deoxycorticosterone and [(3)H]17-hydroxyprogesterone to 11-deoxycortisol, and assessed by thin layer chromatography and phosphorimaging. RESULTS: The A503V POR variant was found in 10 of 30 alleles, the same ratio as in the normal population. There were no significant differences in Michaelis constant, maximum velocity and maximum velocity/Michaelis constant of 21-hydroxylase activity supported by wild-type and A503V POR. CONCLUSION: The only POR missense polymorphism found in atypical 21OHD patients was A503V. Although A503V reduces P450c17 enzymatic activity, it does not influence P450c21 activity, indicating that POR A503V does not modify the 21OHD phenotype.
Authors: S Nimkarn; B I Cerame; J Q Wei; M Dumic; R Zunec; L Brkljacic; V Skrabić; M I New; R C Wilson Journal: J Clin Endocrinol Metab Date: 1999-01 Impact factor: 5.958
Authors: T A Bachega; A E Billerbeck; G Madureira; J A Marcondes; C A Longui; M V Leite; I J Arnhold; B B Mendonca Journal: J Clin Endocrinol Metab Date: 1998-12 Impact factor: 5.958
Authors: Ningwu Huang; Amit V Pandey; Vishal Agrawal; William Reardon; Pablo D Lapunzina; David Mowat; Ethylin Wang Jabs; Guy Van Vliet; Joseph Sack; Christa E Flück; Walter L Miller Journal: Am J Hum Genet Date: 2005-03-25 Impact factor: 11.025
Authors: T A Bachega; A E Billerbeck; G Madureira; I J Arnhold; M A Medeiros; J A Marcondes; C A Longui; W Nicolau; W Bloise; B B Mendonca Journal: Hum Hered Date: 1999-01 Impact factor: 0.444
Authors: Tânia A S S Bachega; Enecy M L Brenlha; Ana E C Billerbeck; José A M Marcondes; Guiomar Madureira; Ivo J P Arnhold; Berenice B Mendonca Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Christa E Flück; Toshihro Tajima; Amit V Pandey; Wiebke Arlt; Kouji Okuhara; Charles F Verge; Ethylin Wang Jabs; Berenice B Mendonça; Kenji Fujieda; Walter L Miller Journal: Nat Genet Date: 2004-02-01 Impact factor: 38.330
Authors: Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini Journal: Mol Cell Endocrinol Date: 2010-11-09 Impact factor: 4.102
Authors: Mária Tomková; Christopher C Marohnic; David Gurwitz; Ondřej Seda; Bettie Sue Siler Masters; Pavel Martásek Journal: Pharmacogenomics Date: 2012-04 Impact factor: 2.533
Authors: Duanpen Sandee; Kari Morrissey; Vishal Agrawal; Harrison K Tam; Melissa A Kramer; Timothy S Tracy; Kathleen M Giacomini; Walter L Miller Journal: Pharmacogenet Genomics Date: 2010-11 Impact factor: 2.089
Authors: Larissa G Gomes; Ningwu Huang; Vishal Agrawal; Berenice B Mendonça; Tania A S S Bachega; Walter L Miller Journal: J Clin Endocrinol Metab Date: 2008-10-28 Impact factor: 5.958
Authors: Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White Journal: Endocr Rev Date: 2022-01-12 Impact factor: 19.871